Clinical Research Directory
Browse clinical research sites, groups, and studies.
Migraine Medication Effects on Urinary Symptoms
Sponsor: The Cleveland Clinic
Summary
A prospective observational cohort trial to study the effects of CGRP inhibitors (CGRPi) on lower urinary tract symptoms (LUTS) and bladder/pelvic pain. Candidates for either CGRPi or an alternative therapy for refractory migraines (OnabotulinumtoxinA (BoNTA) extracranial muscle injections) with baseline LUTS will be recruited. The investigators will assess LUTS and pelvic pain using validated symptom and quality-of-life questionnaires, pretreatment and at 3 months post-treatment follow-up, comparing change in symptoms based on treatment received.
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
200
Start Date
2024-04-05
Completion Date
2026-12
Last Updated
2025-10-01
Healthy Volunteers
No
Conditions
Interventions
Ubrogepant
Ubrogepant (Ubrelvy™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
Rimegepant
Rimegepant (Nurtec®), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
Atogepant
Atogepant (Qulipta™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
Eptinezumab
Eptinezumab (Vyepti®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
Fremanezumab
Fremanezumab (Ajovy®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
Galcanezumab
Galcanezumab (Emgality®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
Erenumab
Erenumab (Aimovig®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
Botulinum toxin A
Botolinum toxin A (Botox) injections into extracranial muscles, dosage at discretion of clinical provider, for treatment of migraines.
Locations (1)
Cleveland Clinic, Main Campus
Cleveland, Ohio, United States